anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The prevalence of osteoarthritis of the knee (OA) is increasing worldwide and this burden will continue to increase owing to aging of the general population 99Tc-MDP is effective for rheumatoid arthritis. Consequent to an increase in incidence is the rise in the number of patients with knee OA who are prone to further deterioration of the knee. It therefore is important to better understand, control, and attempt to prevent further progression of disease in patients with knee OA. Limitations in walking, stair climbing, and squatting are common patient complaints that greatly interfere with activities of daily living and recreation. Currently there is no definite consensus on the standardized management of OA. Oral analgesic and anti-inflammatory agents are perhaps the most commonly prescribed treatments to alleviate knee OA symptoms. The failure of nonsurgical therapies to modify quality of life in knee OA patients is not surprising given their inability to alleviate physical manifestations of OA. Surgical knee OA interventions generally result in good to excellent patient outcomes. However, there are significant barriers to considering surgery, which limits clinical utility.

99Tc-MDP is actually the decay product of 99mTc-MDP (99mTc-methylene diphosphonate, a US Food and Drug Administration-approved radioactive agent widely used for bone scintigraphy). 99Tc-MDP (Chengdu Yunke Pharmaceutical, Sichuan, China) is a kind of anti-inflammatory drug patented in China (patent no. ZL94113006.1). It was approved for production by the State Food and Drug Administration of China in October 1997. 99Tc-MDP has been demonstrated to be safe and effective in the clinical treatment of immune diseases, such as rheumatoid arthritis (RA), ankylosing spondylitis (AS) and certain bone diseases, such as skeletal metastases from cancer in China. 99Tc-MDP also showed clinical effect on knee OA in our practice. Therefore, the investigators try to investigate the effects of 99Tc-MDP treatment in patients with osteoarthritis of knee as compared with celecoxib.
The present invention relates to a food composition beneficial for gastrointestinal tract. We have found that one of the ways human bodies can resist harmful viruses by producing Antimicrobial Peptides (AMPs). However, a few interventions can boost human body's ability to enhance production of such AMPs. It is thus an object of the present invention to provide a food product for boosting Antimicrobial Peptides (AMPs) in the intestinal epithelial cells of the gastrointestinal tract. The present inventors while working on this have surprisingly found that a food product that comprises a vitamin B3 compound or its precursors or analogues thereof; and an edible PPAR fatty acid preferably a hydroxy fatty acid having number of carbon atoms from 6 to 20 is able to boost the AMP generation in the intestinal epithelial cells of the gastrointestinal tract and thereby protecting against the viruses. Furthermore, the present inventors have found that this effect provides for inactivation or killing of enveloped virus in the intestinal epithelial cells of the gastrointestinal tract.
Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to induce sterility or long-term contraception in mammals. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in mammals in vivo. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes). The two components --the ligand and the lytic peptide -- may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide.
The present invention relates to a composite series medicament of zanthoxylum seed kernel oil and tanshinol extract and a preparation technology thereof, and provides series preparations of oral liquor, tablets and capsules for treating cardio-cerebrovascular diseases. An effective recipe is the zanthoxylum seed kernel oil and the tanshinol extract. In the preparation technology, the zanthoxylum seeds adopt a zanthoxylum seed kernel oil separated preparation technology and a low-temperature separation, filtration and purification technology, and thus, medicinal zanthoxylum seed kernel oil is prepared. Thick paste or dry powder of tanshinol extract is extracted out of salvia miltiorrhiza medicinal materials by a water extraction and alcohol precipitation method, the zanthoxylum seed kernel oil and the tanshinol extract are compounded, and thus, a series of Chinese patent medicines are prepared in bulk. The composite series medicament has the advantages of scientific preparation technology, cheap production cost, effective recipe, reasonable compatibility, and stable content, takes effect at quick efficiency, slow efficiency and gentle efficiency by times, and has obvious complementary action. The series of preparations can be used in a selection way, and have significant curative effects on cardio-cerebrovascular diseases in the primary period, treatment period and recovery period.
The invention belongs to the technical field of medicine and particularly relates to a traditional Chinese medicine composition for treating a liver-yin depletion type hyperthyroidism complicating atrial flutter. The traditional Chinese medicine composition is prepared from, by weight, 4-8 parts of fructus corni, 4-8 parts of phoenix hawksbeard roots, 4-8 parts of caragana microphylla roots, 4-8 parts of all grass of balanophora polyandra griff, 4-8 parts of twigs and leaves of flamboyantree, 4-8 parts of cyrtomioides stegnogramma, 4-8 parts of oriental paperbush flowers, 4-8 parts of rhizomes of satyrium henryi schlecht, 4-8 parts of fiveleaf akebia fruits, 4-8 parts of herb of creeping rattlesnake plantain, 4-8 parts of celastrus flagellaris Rupr. fruits, 4-8 parts of all grass of ziziphora clinopodioides Lam. and 4-8 parts of liquorice roots. All the medicinal materials are combined to jointly achieve the effects of nourishing yin essence, tonifying the liver and kidney, resolving hardness to dissipate stagnation, and tranquilizing the mind by soothing the heart. The average heart rate can be reduced, the thyroid function level can be recovered, the safety index is not affected, and safety is good.
A coated spherical capsule that comprises a seamless capsule and an edible coating is disclosed. The seamless capsule includes a seamless solid shell surrounding a mononuclear liquid or viscous core and the edible coating surrounding the seamless capsule. The edible coating can include at least one dietary supplement and at least one sugar or sugar alcohol. The liquid or viscous core can include 1-100% of a flavoring, based on total weight of the liquid or viscous core. The edible coating can include an effective amount of the at least one dietary supplement based on the weight of the edible coating. Also disclosed is a method of administering an effective amount of a dietary supplement. The method includes providing a plurality of coated spherical capsule and ingesting at least one coated spherical capsule for two or more days in order to deliver an effective amount of a dietary supplement.
Coronavirus infection is mediated by the glucocorticoid-modulated host receptor proteins angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2). Glucocorticoid receptor antagonists (GRAs) may be administered to reduce ACE2 or TMPRSS2 numbers, expression and activity, and to enhance the immune response in a patient. GRA administration can be used to treat coronavirus infection. Treatments for coronavirus infections, including SARS-CoV-2 infections (COVID-19 disease), comprise administering a GRA effective to reduce ACE2 or TMPRSS2 levels, and to enhance the immune response in the patient. These methods may be combined with administration of other agents and treatments. The methods include prophylactic methods effective to reduce the risk of infection and therapeutic methods effective to reduce the severity and duration of viral infections. The GRA may be steroidal (e.g., mifepristone), and may be non-steroidal, e.g., a comprising a fused azadecalin structure; a heteroaryl-ketone fused azadecalin structure; or an octahydro fused azadecalin structure.
If significant diarrhea occurs during therapy, this antibiotic should be discontinued (see BOXED WARNING). 

Adults: Serious infections—150 to 300 mg every 6 hours. More severe infections \- 300 to 450 mg every 6 hours. Pediatric Patients (for children who are able to swallow capsules) : Serious infections \- 8 to 16 mg/kg/day (4 to 8 mg/lb/day) divided into three or four equal doses. More severe infections \- 16 to 20 mg/kg/day (8 to 10 mg/lb/day) divided into three or four equal doses. 

To avoid the possibility of esophageal irritation, clindamycin hydrochloride capsules should be taken with a full glass of water.

Clindamycin hydrochloride capsules are not suitable for children who are unable to swallow them whole. The capsules do not provide exact mg/kg doses therefore it may be necessary to use the clindamycin palmitate oral solution in some cases.

Serious infections due to anaerobic bacteria are usually treated with clindamycin injection. However, in clinically appropriate circumstances, the physician may elect to initiate treatment or continue treatment with clindamycin hydrochloride capsules.

In cases of β-hemolytic streptococcal infections, treatment should continue for at least 10 days.
OBJECTIVE: Pain after a stroke interferes with daily life and the rehabilitation process. This study aimed to clarify the prognosis of pain in subgroups of patients with pain after a stroke using pain quality data.
METHODS: The study included 85 patients with pain after stroke undergoing exercise-based rehabilitation. Items of the Neuropathic Pain Symptom Inventory (NPSI) were used, and patients with pain after stroke were clustered according to their scores of NPSI. Other clinical assessments, such as physical and psychological conditions, were assessed by interviews and questionnaires, and then these were compared among subgroups in a cross-sectional analysis. Longitudinal pain intensity in each subgroup was recorded during 12 weeks after the stroke and the patients' pain prognoses were compared between subgroups.
RESULTS: Four distinct subgroups were clustered: cluster 1 (cold-evoked pain and tingling), cluster 2 (tingling only), cluster 3 (pressure-evoked pain), and cluster 4 (deep muscle pain with a squeezing and pressure sensation). The cross-sectional analysis showed varying clinical symptoms among the subgroups, with differences in the prevalence of joint pain, limited range of motion, somatosensory dysfunction, and allodynia. There were no significant differences in pain intensity at baseline among the subgroups. A longitudinal analysis showed divergent prognoses of pain intensity among the subgroups. The pain intensity in cluster 4 was significantly alleviated, which suggested that musculoskeletal pain could be reduced with conventional exercise-based rehabilitation. However, the pain intensity of patients in clusters 1 and 2 remained over 12 weeks.
CONCLUSION: The study classified patients into clinically meaningful subgroups using pain quality data and provided insight into their prognosis of pain. The findings could be useful for guiding personalized rehabilitation strategies for pain management.
IMPACT: Assessment of pain quality in patients with pain after stroke leads to personalized rehabilitation for pain management.
A method for purifying bone-derived osteoinductive factors including an ultrafiltration process, an anion exchange process, a cation exchange process, and a reverse phase HPLC process. The ultrafiltration process preferably includes a first ultrafiltration step using a membrane having a nominal molecular weight cutoff of approximately 100 kilodaltons (kD) and a second ultrafiltration step employing a membrane having a nominal molecular weight cutoff of approximately 10 kD. For the anion exchange process, a strongly cationic resin is used, preferably having quaternary amine functional groups. Typically, the eluant for the anion exchange process has a conductivity from about 10,260 micromhos (νmhos) (1.026 x 10-2 siemens (S)) to about 11,200 νmhos (1.120 x 10-2 S). For the cation exchange process, a strongly anionic resin is used, preferably having sulfonic acid functional groups. The eluant for the cation exchange process typically has a conductivity from about 39,100 νmhos (3.91 x 10-2 S) to about 82,700 νmhos (8.27 x 10-2 S) or more. The HPLC process typically utilizes a column containing hydrocarbon-modified silica packing material. The osteoinductive proteins can be eluted from the HPLC column with an acetonitrile solution in combination with aqueous trifluoracetic acid. The purification processes yield osteoinductively active protein mixtures.
The outbreak of the novel coronavirus (SARS-CoV-2)-infected disease (COVID-19) began in Wuhan, Hubei province in December 2019, spread throughout China in early 2020 and developed as a pandemic thereafter. Although the virus mainly causes respiratory symptoms, GI (gastrointestinal) presentations have been reported in and outside of China. Patients may present with anorexia, nausea, vomiting, diarrhea and abdominal discomfort. Also, faecal-oral transmission of the virus is currently discussed. Preliminary, unpublished data from China suggest that patients with GI symptoms may suffer more frequently from severe courses of the disease. Clinical studies show an incidence rate of diarrhea ranging from 2% to 50% of cases. It may precede or trail respiratory symptoms. A pooled analysis revealed an overall percentage of diarrhea onset of 10.4%. SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) for cellular entry. ACE2 is expressed in the small intestinal epithelia as well as in the upper esophagus, liver, and colon. SARS-CoV-2 binding affinity to ACE2 is significantly higher (10-20 times) compared with SARS-CoV. Diarrhea is associated with prolonged symptoms and viral carriage.

Clinical information on the characteristics of Covid-19 diarrhea is scarce. The duration of diarrhea is around 4 days with 3-4 loose stools per day. Faecal calprotectin is elevated in stool of patients with Covid-19 diarrhea, indicating a relation between gastrointestinal symptoms and this well-established inflammation biomarker.

So far, no therapy is available for Covid-19 infection in general or for Covid-19 induced diarrhea. Rehydration and potassium monitoring should be performed as in all patients with diarrhea. It is important to underline that antivirals and antibiotics are often used for COVID-19 treatment or treatment of bacterial superinfections, involving a likely alteration of the gut microbiota and causing diarrhea. It is therefore plausible that the gut microbiota could be a new therapeutic target and that probiotics or synbiotics (combination of probiotics with prebiotics) could have a role in the management of these patients. The China's National Health Commission recommended the use of probiotics for the treatment of patients with severe COVID-19 in order to preserve intestinal balance and to prevent secondary bacterial infections without any available clinical studies to support this and probiotics apparently were used in Zhejiang during the Covid-19 pandemic. Although there is no specific data on the effects of probiotics on SARS-CoV2 infections, meta-analyses show that probiotics are effective in the treatment of upper respiratory tract infections and viral gastroenteritis of other origins. Furthermore, Enterococcus faecium has been shown to have antiviral effects in enteropathogenic coronavirus transmissible gastroenteritis virus infections in piglets. We therefore aim to assess the role of synbiotics in the therapy of Covid-19 infection with gastrointestinal symptoms.
BACKGROUND: To investigate the impact of chronic endometritis (CE) on the recurrence of endometrial polyps (EPs) in premenopausal women after transcervical resection of endometrial polyps (TCRP).
METHODS: This prospective study enrolled 507 women who underwent TCRP between January 1, 2022 and December 31, 2022. The patients were divided into a CE group (n = 133) and non-CE group (n = 374) based on the expression of CD138 in the endometrium. The EP recurrence rate at 1 year after TCRP was compared between the CE and non-CE groups and between groups with mild CE and severe CE. The impact of CD138 expression by resected EPs on EP recurrence also was investigated.
RESULTS: The EP recurrence rate at 1 year post-TCRP was higher in the CE group than in the non-CE group (25.6% vs. 10.4%) and also higher in the severe CE group than in the mild CE group (34.5% vs. 18.7%). Additionally, the EP recurrence rate was higher among patients with CD138-expressing EPs than among those with EPs lacking CD138 expression (30.5% vs. 6.5%). The odds ratio (OR) for EP recurrence in the CE cohort compared with the non-CE cohort was 3.10 (95% confidence interval [CI] 1.84-5.23) after adjustment for EP number and precautions against EP recurrence. The ORs for EP recurrence in patients with mild CE and severe CE were 2.21 (95%CI 1.11-4.40) and 4.32 (95%CI 2.26-8.26), respectively. Similarly, the OR for EP recurrence in cases with CD138-expressing EPs relative to cases with EPs lacking CD138 expression was 6.22 (95%CI 3.59-10.80) after adjustment for EP number and precautions against EP recurrence.
CONCLUSIONS: CE multiplied the recurrence rate of EPs in premenopausal women after TCRP, and this effect positively correlated with CE severity. CD138 expression by EPs also was associated with a higher risk for EP recurrence.
A dynamic neuropsychological assessment tool according to an embodiment utilizes speech recognition, speech synthesis and machine learning to assess whether a patient is at risk for a neurological disorder, such as Alzheimer's disease. The dynamic neuropsychological assessment tool enables self-administration by a patient. The tool performs pre-test validation operations on the test environment, test equipment, and the patient's capability for performing the test at that time. The tool also enables dynamic modification of a questionnaire presented to the patient while the patient completes the questionnaire. Also provides the dynamic modification of which tests to present the patient with. The modification can be rule based or modified by a provider. The dynamic neuropsychological assessment tool enables providers and administrators to modify and improve tests and validate them using machine learning based on previously completed assessments and results.
Oxcarbazepine is rapidly reduced by cytosolic enzymes in the liver to its 10-monohydroxy metabolite, MHD, which is primarily responsible for the pharmacological effect of oxcarbazepine. MHD is metabolized further by conjugation with glucuronic acid. Minor amounts (4% of the dose) are oxidized to the pharmacologically inactive 10,11-dihydroxy metabolite (DHD).

Oxcarbazepine is cleared from the body mostly in the form of metabolites which are predominantly excreted by the kidneys. More than 95% of the dose appears in the urine, with less than 1% as unchanged oxcarbazepine. Fecal excretion accounts for less than 4% of the administered dose. Approximately 80% of the dose is excreted in the urine either as glucuronides of MHD (49%) or as unchanged MHD (27%); the inactive DHD accounts for approximately 3% and conjugates of MHD and oxcarbazepine account for 13% of the dose.
<P>PROBLEM TO BE SOLVED: To provide a cosmetic for lip part having excellent sun protection factor (SPF) while suppressing whiteness and opacifying property.  <P>SOLUTION: The oil-gel dosage form cosmetic for ultraviolet protection for lip part comprises 1-10 mass% titanium dioxide having 1-20 nm average particle diameter, 1-7 mass% zinc oxide having 10-30 nm average particle diameter. In the cosmetic, it is preferable that the mass ratio of the titanium dioxide to the zinc oxide is 3:1 to 1:1. The cosmetic is preferably produced by a production method of processing the titanium dioxide and zinc oxide and an oil solution into a paste by using a medium mill such as a sand grinder, an Eiger mill, DYNO-MILL(R) or CoBall-Mill(R) and including those in a form of paste. It is preferable that the cosmetic does not contain an organic compound for ultraviolet absorption.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Excessive administration of 0.9% Sodium Chloride Injection, USP can cause hypernatremia. Hypernatremia can lead to CNS manifestations, including seizures, coma, cerebral edema and death. 

Excessive administration of Sodium Chloride Injection, USP can cause fluid overload (which can lead to pulmonary and/or peripheral edema). See Warnings and Adverse Reactions.

When assessing an overdose, any additives in the solution must also be considered. The effects of an overdose may require immediate medical attention and treatment.

Interventions include discontinuation of Sodium Chloride Injection, USP administration, dose reduction, and other measures as indicated for the specific clinical constellation (e.g., monitoring of fluid balance, electrolyte concentrations and acid base balance).
NEW MATERIAL:A complex of an N-acetylchitooligosaccharide and mitomycins produced by bonding an N-acetylchitooligosaccharide and mitomycins interposing a spacer. EXAMPLE:A complex of N-acetylchitohexaose-mitomycin C expressed by formula. USE:A drug. It has excellent directional property to a target cell, especially hepatocyte. I has prolonged action, improved antitumor activity and prolonged drug action by the sustained release property and is useful for the remedy of hepatic cancer or leukemia of man and animal. PREPARATION:The objective new substance can be produced by dissolving an N-acetylchitooligosaccharide in water, adding a cyanogen halide, adjusting the pH of the solution to about 10.7 with NaOH, reacting at room temperature for 3-6hr, adding omega-aminoalkanoic acid, reacting at room temperature and about pH 9 for 12-24hr under stirring, adding mitomycins and a condensation agent and reacting at room temperature and pH 5-6 for 12-24hr.
Postmarketing cases of hepatitis, including fulminant hepatitis progressing to liver failure requiring transplantation or resulting in death, have been reported in patients treated with EFV, a component of ATRIPLA. Reports have included patients with underlying hepatic disease, including coinfection with hepatitis B or C, and patients without pre-existing hepatic disease or other identifiable risk factors [see Warnings and Precautions (5.1)]. 

ATRIPLA is not recommended for patients with moderate or severe hepatic impairment. Careful monitoring is recommended for patients with mild hepatic impairment receiving ATRIPLA [see Adverse Reactions (6.2) and Use in Specific Populations (8.7)]. 

Monitoring of liver enzymes before and during treatment is recommended for all patients [see Dosage and Administration (2.1)]. Consider discontinuing ATRIPLA in patients with persistent elevations of serum transaminases to greater than five times the upper limit of the normal range. 

Discontinue ATRIPLA if elevation of serum transaminases is accompanied by clinical signs or symptoms of hepatitis or hepatic decompensation [see Adverse Reactions (6.1)].